Studies and Articles on Champix
Cost effectiveness of Champix on the NHS, December 2009
The study investigated the cost-utility of the new smoking-cessation agent varenicline compared with other pharmacological options for smokers. The authors concluded that varenicline was a cost-effective treatment strategy in the USA and dominated the other options as it was more effective and less costly.
Cost effectiveness of Champix on the NHS, December 2009.
Champix and suicidal behaviour, BMJ October 2009
Although a twofold increased risk of self harm with varenicline cannot be ruled out, the report findings provide some reassurance concerning its association with suicidal behaviour.
Champix and suicidal behaviour, BMJ October 2009.
Varenicline and smokers with mental illness, Lancet October 2008
Smoking is the leading preventable cause of death in the USA, and people with mental illnesses smoke nearly half of all cigarettes in that country. We were thus surprised to note that some people with mental illnesses were systematically excluded from the premarketing trials of the newest smoking cessation drug, varenicline.
Varenicline and smokers with mental illness, Lancet October 2008.
Cochrane Review 2008 Nicotine receptor partial agonist for smoking cessation
From the data, varenicline (Champix) increased the chances of quitting between two- and three-fold compared with placebo.
Cochrane Review 2008 Nicotine receptor partial agonist for smoking cessation
American Family Physician Drug Review, July 2007
For every nine highly-motivated patients who use varenicline instead of placebo, one will not be smoking one year later. Although the cost of therapy is a limitation (total cost is approximately $360 for a three-month course), the easy dosage titration, lack of drug interactions, and favourable side-effect profile make varenicline an appealing alternative to sustained-release bupropion for smoking cessation.
American Family Physician Drug Review, July 2007
